Potentantimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762

Blood

Volumn 123, Issue 5, 2014, Pages 697-705

  Chaidos, Aristeidis ^a   Caputo, Valentina ^a   Gouvedenou, Katerina ^a   Liu, Binbin ^a   Marigo, Ilaria ^a   Chaudhry, Mohammed Suhail ^a   Rotolo, Antonia ^a   Tough, David F ^b   Smithers, Nicholas N ^b   Bassil, Anna K ^b   Chapman, Trevor D ^b   Harker, Nicola R ^b   Barbash, Olena ^c   Tummino, Peter ^c   Al Mahdi, Niam ^b   Haynes, Andrea C ^b   Cutler, Leanne ^b   Le, BaoChau ^b   Rahemtulla, Amin ^a   Roberts, Irene ^a   Kleijnen, Maurits ^a   Witherington, Jason J ^b   Parr, Nigel J ^b   Prinjha, Rab K ^b   Karadimitris, Anastasios ^a   more..

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMODOMAIN AND EXTRATERMINAL PROTEIN; I BET 151; I BET 762; MYC PROTEIN; PEPTIDES AND PROTEINS; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; GSK1210151A; GSK525762A; HEXIM1 PROTEIN, HUMAN; RNA BINDING PROTEIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMYELOMA ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; DRUG ACTIVITY; GENE EXPRESSION PROFILING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE CHECKPOINT; DOWN REGULATION; DRUG EFFECT; GENETICS; HUMAN; PATHOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZODIAZEPINES; CELL CYCLE CHECKPOINTS; DOWN-REGULATION; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MICE; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-MYC; RNA-BINDING PROTEINS; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED;

EID: 84897024898     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-478420     Document Type: Article

References (43)

1. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol. 2011;6:249-274.
2. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335-348.
3. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23(26):6333-6338. (Pubitemid 46218843)
4. Kumar SK, Lee JH, Lahuerta JJ, et al International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1):149-157.
5. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128(4):693-705. (Pubitemid 46273577)
6. Wu SY, Chiang CM. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem. 2007;282(18):13141-13145.
7. Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell. 2005;19(4):523-534. (Pubitemid 41140009)
8. Yang Z, Yik JH, Chen R, et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005;19(4):535-545. (Pubitemid 41140010)
9. Brès V, Yoh SM, Jones KA. The multi-tasking P-TEFb complex. Curr Opin Cell Biol. 2008;20(3):334-340.
10. Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N Engl J Med. 2012;367(7):647-657.
11. Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478(7370):529-533.
12. Prinjha RK, Witherington J, Lee K. Place your BETs: the therapeutic potential of bromodomains. Trends Pharmacol Sci. 2012;33(3):146-153.
13. Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067-1073.
14. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904-917.
15. Mertz JA, Conery AR, Bryant BM, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A. 2011;108(40):16669- 16674.
16. Ott CJ, Kopp N, Bird L, et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012;120(14):2843-2852.
17. Chng WJ, Huang GF, Chung TH, et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia. 2011;25(6):1026-1035.
18. Kuehl WM, Bergsagel PL. MYC addiction: a potential therapeutic target in MM. Blood. 2012;120(12):2351-2352.
19. Fonseca R, Bergsagel PL, Drach J, et al International Myeloma Working Group. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210-2221.
20. Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468(7327):1119-1123.
21. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19(2):185-193. (Pubitemid 36181903)
22. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550. (Pubitemid 41528093)
23. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020-2028. (Pubitemid 44395016)
24. Schuhmacher M, Kohlhuber F, Hölzel M, et al. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res. 2001;29(2):397-406. (Pubitemid 32060926)
25. Heller G, Schmidt WM, Ziegler B, et al. Genome-wide transcriptional response to 5-aza-2′-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res. 2008;68(1):44-54. (Pubitemid 351380104)
26. Nutt SL, Taubenheim N, Hasbold J, Corcoran LM, Hodgkin PD. The genetic network controlling plasma cell differentiation. Semin Immunol. 2011;23(5):341-349.
27. Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 2008;454(7201):226-231. (Pubitemid 351969894)
28. Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau JL, Bataille R; Intergroupe Francophone du Myélome. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood. 2001;98(10):3082-3086.
29. Lombardi L, Poretti G, Mattioli M, et al. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes Chromosomes Cancer. 2007;46(3):226-238. (Pubitemid 46155318)
30. He N, Pezda AC, Zhou Q. Modulation of a P-TEFb functional equilibrium for the global control of cell growth and differentiation. Mol Cell Biol. 2006;26(19):7068-7076. (Pubitemid 44477686)
31. Cho S, Schroeder S, Kaehlcke K, et al. Acetylation of cyclin T1 regulates the equilibrium between active and inactive P-TEFb in cells. EMBO J. 2009;28(10):1407-1417.
32. Dey A, Chao SH, Lane DP. HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy. Cell Cycle. 2007;6(15):1856-1863. (Pubitemid 47327903)
33. Biglione S, Byers SA, Price JP, et al. Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology. 2007;4:47.
34. Bartholomeeusen K, Xiang YH, Fujinaga K, Peterlin BM. Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J Biol Chem. 2012;287(43):36609-36616.
35. Holien T, Våtsveen TK, Hella H, Waage A, Sundan A. Addiction to c-MYC in multiple myeloma. Blood. 2012;120(12):2450-2453.
36. Diribarne G, Bensaude O. 7SK RNA, a non-coding RNA regulating P-TEFb, a general transcription factor. RNA Biol. 2009;6(2):122-128.
37. Rahl PB, Lin CY, Seila AC, et al. c-Myc regulates transcriptional pause release. Cell. 2010;141(3):432-445.
38. Anderson KC. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol. 2007;35(4 Suppl 1):155-162. (Pubitemid 46427993)
39. Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell. 2004;6(5):439-444. (Pubitemid 39469979)
40. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332(6159):83-85.
41. Frassanito MA, Cusmai A, Iodice G, Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood. 2001;97(2):483-489. (Pubitemid 32060334)
42. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277(19):16639-16647. (Pubitemid 34967682)
43. French CA. NUT midline carcinoma. Cancer Genet Cytogenet. 2010;203(1):16-20.